0
0
Emerging research and updated clinical guidelines have raised important questions about the routine use of daily aspirin among middle-aged adults for preventing cardiovascular disease (CVD). Recent studies indicate that for many individuals without prior heart conditions, the risks of aspirin—particularly bleeding complications—may outweigh potential benefits. Experts now urge a more cautious, personalized approach to aspirin use, emphasizing that broad recommendations for primary prevention may no longer be appropriate.
A large new assessment published in 2025 evaluated aspirin use among middle-aged adults in the United States, analyzing cardiovascular risk criteria and aspirin eligibility. The findings revealed that only a small fraction—about 8.3% by one risk model and even fewer by another—should be considered appropriate candidates for aspirin therapy to prevent initial heart attacks or strokes. Meanwhile, millions currently taking aspirin daily for prevention do not meet these criteria and are exposed unnecessarily to potential harms.
Key Findings
This comprehensive evaluation found that 97% of middle-aged adults taking aspirin daily for prevention do not meet recommended eligibility thresholds based on validated cardiovascular risk equations. These findings align with published clinical trial data, including the randomized ASPREE trial led by researchers at Monash University, which showed no long-term benefit of aspirin in healthy older adults for preventing major adverse cardiovascular events (MACE) but an increased risk of serious bleeding, such as gastrointestinal hemorrhage.
The U.S. Preventive Services Task Force (USPSTF) updated its guidance in recent years to reflect emerging evidence. It now recommends that the decision to begin low-dose aspirin for primary prevention in adults aged 40 to 59 years with moderate (≥10%) 10-year cardiovascular risk should be individualized and made with healthcare provider input. For adults aged 60 years or older, the USPSTF recommends against routine aspirin initiation for primary prevention due to lack of net benefit and higher bleeding risk.
Expert Perspectives
Dr. Rory Wolfe, PhD, lead investigator of the ASPREE extended trial, notes, “Our data demonstrate that aspirin does not provide a significant protective effect against cardiovascular events in healthy older adults and increases major bleeding risk. This underscores the need to reconsider routine aspirin use, especially in populations without existing heart disease.” Cardiologists emphasize that aspirin remains a cornerstone for secondary prevention after heart attacks or strokes but is much less clear as a preventive measure for those without prior events.
Context and Background
Aspirin acts by inhibiting platelet aggregation to reduce blood clot formation, which can precipitate heart attacks and strokes. This mechanism has proven beneficial in patients with established atherosclerotic cardiovascular disease. However, for primary prevention—preventing the first cardiovascular event—benefit is more modest and must be balanced against the increased risk of bleeding complications. Improved control of other cardiovascular risk factors such as hypertension, cholesterol, and smoking cessation has also reduced the incremental benefit of aspirin in recent decades.
Implications for Public Health and Daily Decisions
For the general population, these findings suggest that taking daily aspirin without a clear indication could expose many to unnecessary harm without reducing their cardiovascular risk. Healthcare professionals are encouraged to evaluate individual risk factors using validated tools and engage patients in informed discussions about aspirin’s benefits and risks before recommending its use. Patients should not start or stop aspirin therapy without consulting their healthcare providers.
Limitations and Counterarguments
While current data strongly advise against widespread aspirin use in primary prevention for older adults, certain subgroups—such as individuals with diabetes or those at particularly high cardiovascular risk but low bleeding risk—may still benefit. Ongoing research aims to better identify these patients. Observational differences in aspirin response and the risk-benefit balance underline the need for personalized medical decisions.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
